Bank Of New York Mellon Corp Viracta Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $15,978 - $55,542	12,681 New	12,681 $18,000
Q2 2022 Aug 15, 2022	SELL	$1.87 - $5.0 $180,432 - $482,440	-96,488 Reduced 88.35%	12,727 $49,000
Q1 2022 May 11, 2022	SELL	$2.23 - $4.76 $1,779 - $3,798	-798 Reduced 0.73%	109,215 $520,000
Q4 2021 Feb 11, 2022	BUY	$3.37 - $7.91 $6,992 - $16,413	2,075 Added 1.92%	110,013 $402,000
Q3 2021 Nov 12, 2021	BUY	$7.84 - $12.53 $75,601 - $120,826	9,643 Added 9.81%	107,938 $866,000
Q2 2021 Aug 11, 2021	BUY	$7.55 - $12.95 $742,127 - $1.27 Million	98,295 New	98,295 $1.11 Million

9.03M

10.9K

400

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $8.26M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.